Which Drugs are More Effective in Preventing Familial Adenomatous Polyposis Progression based on Network Meta-analysis?


Cite item

Full Text

Abstract

Background:Familial adenomatous polyposis (FAP) is an inherited disorder. At present, an increasing number of medications are being employed to treat FAP; however, only a few have been assessed for their efficacy and safety. Therefore, this study aimed to conduct a network meta-analysis to compare the therapeutic outcomes and adverse drug reactions of all FAP-associated medications.

Methods:Six relevant databases were searched to identify pertinent randomized controlled trials (RCTs), and information on the dosage and frequency of various drugs was extracted. Additionally, data on changes in polyp counts and dimensions, as well as treatment-related adverse reactions for different medications were collected. The Bayesian method was employed to directly or indirectly compare the impact of different treatment regimens on changes in polyp numbers and diameters, and the safety of the drugs was investigated.

Results:CXB at 16 mg/kg/day significantly reduced polyp numbers. Celecoxib at 8 mg/kg/day and sulindac (150 mg twice daily) plus erlotinib (75 mg/day) were effective for tolerant FAP patients. Additionally, EPAFFA 2 g daily and sulindac (150 mg twice daily) plus erlotinib (75 mg/day) emerged as the most effective for reducing polyp size.

Conclusion:The most effective treatment for reducing the number of colorectal polyps is celecoxib 16 mg/kg/day. On the other hand, a daily dosage of 2 g EPA-FFA demonstrates the best results in terms of decreasing colorectal polyp diameter.

About the authors

Pei Luo

Colorectal Surgery Department, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University

Email: info@benthamscience.net

Wenjun Shi

Colorectal Surgery Department, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University

Email: info@benthamscience.net

Xianshuo Cheng

Colorectal Surgery Department, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University

Email: info@benthamscience.net

Jun Yang

Colorectal Surgery Departmen, The First Affiliated Hospital of Kunming Medical University

Email: info@benthamscience.net

Gen Pei

Colorectal Surgery Department, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University

Email: info@benthamscience.net

Jian Dong

Colorectal Surgery Department, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009; 4(1): 22. doi: 10.1186/1750-1172-4-22 PMID: 19822006
  2. Dinarvand P, Davaro EP, Doan JV, et al. Familial adenomatous polyposis syndrome: An update and review of extraintestinal manifestations. Arch Pathol Lab Med 2019; 143(11): 1382-98. doi: 10.5858/arpa.2018-0570-RA PMID: 31070935
  3. Laurent S, Franchimont D, Coppens JP, et al. Familial adenomatous polyposis: Clinical presentation, detection and surveillance. Acta Gastroenterol Belg 2011; 74(3): 415-20. PMID: 22103047
  4. Dolan S. Familial adenomatous polyposis: Development, presentation, and treatment strategies. Clin J Oncol Nurs 2019; 23(2): 135-8. doi: 10.1188/19.CJON.135-138 PMID: 30880794
  5. Aihara H, Kumar N, Thompson CC. Diagnosis, surveillance, and treatment strategies for familial adenomatous polyposis. Eur J Gastroenterol Hepatol 2014; 26(3): 255-62. doi: 10.1097/MEG.0000000000000010 PMID: 24161962
  6. Stanich PP, Sullivan B, Kim AC, Kalady MF. Endoscopic management and surgical considerations for familial adenomatous polyposis. Gastrointest Endosc Clin N Am 2022; 32(1): 113-30. doi: 10.1016/j.giec.2021.08.007 PMID: 34798980
  7. Vitellaro M, Ferrari A, Trencheva K, et al. Is laparoscopic surgery an option to support prophylactic colectomy in adolescent patients with Familial Adenomatous Polyposis (FAP)? Pediatr Blood Cancer 2012; 59(7): 1223-8. doi: 10.1002/pbc.24113 PMID: 22378577
  8. Kemp Bohan PM, Mankaney G, Vreeland TJ, et al. Chemoprevention in familial adenomatous polyposis: past, present and future. Fam Cancer 2021; 20(1): 23-33. doi: 10.1007/s10689-020-00189-y PMID: 32507936
  9. Vasen HFA, Möslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57(5): 704-13. doi: 10.1136/gut.2007.136127 PMID: 18194984
  10. Lynch PM. Low-dose aspirin and mesalazine for patients with familial adenomatous polyposis. Lancet Gastroenterol Hepatol 2021; 6(6): 418-9. doi: 10.1016/S2468-1253(21)00102-3 PMID: 33812493
  11. Herendeen JM, Lindley C. Use of NSAIDs for the chemoprevention of colorectal cancer. Ann Pharmacother 2003; 37(11): 1664-74. doi: 10.1345/aph.1C489 PMID: 14565811
  12. Roser C, Tóth C, Renner M, Herpel E, Schirmacher P. Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin. Cell Commun Signal 2021; 19(1): 15. doi: 10.1186/s12964-020-00702-x PMID: 33579312
  13. Shi YJ, Zhao QQ, Liu XS, et al. Toll‐like receptor 4 regulates spontaneous intestinal tumorigenesis by up‐regulating IL‐6 and GM‐CSF. J Cell Mol Med 2020; 24(1): 385-97. doi: 10.1111/jcmm.14742 PMID: 31650683
  14. Xavier A, Scott RJ, Talseth-Palmer B. Exome sequencing of familial adenomatous polyposis‐like individuals identifies both known and novel causative genes. Clin Genet 2021; 100(4): 478-83. doi: 10.1111/cge.14029 PMID: 34259353
  15. Paziewska A, Horbacka K, Goryca K, et al. Transcriptional changes between uninflamed ulcerative colitis and familial adenomatous polyposis pouch mucosa can be attributed to an altered immune response. Acta Biochim Pol 2015; 62(1): 69-75. doi: 10.18388/abp.2014_778 PMID: 25654358
  16. Khan N, Lipsa A, Arunachal G, Ramadwar M, Sarin R. Novel mutations and phenotypic associations identified through APC, MUTYH, NTHL1, POLD1, POLE gene analysis in Indian Familial Adenomatous Polyposis cohort. Sci Rep 2017; 7(1): 2214. doi: 10.1038/s41598-017-02319-6 PMID: 28533537
  17. Keane S, Herring M, Rolny P, Wettergren Y, Ejeskär K. Inflammation suppresses DLG2 expression decreasing inflammasome formation. J Cancer Res Clin Oncol 2022; 148(9): 2295-311. doi: 10.1007/s00432-022-04029-7 PMID: 35499706
  18. Shureiqi I. Molecular predicators of duodenal familial adenomatous polyposis chemoprevention: do chemopreventive drugs hit their presumed molecular targets? Cancer Prev Res 2018; 11(1): 1-3. doi: 10.1158/1940-6207.CAPR-17-0372 PMID: 29263155
  19. Benamouzig R, Uzzan B, Little J, Chaussade S. Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer. Curr Top Med Chem 2005; 5(5): 493-503. doi: 10.2174/1568026054201631 PMID: 15974944
  20. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 2015; 162(11): 777-84. doi: 10.7326/M14-2385 PMID: 26030634
  21. Burke CA, Dekker E, Lynch P, et al. Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis. N Engl J Med 2020; 383(11): 1028-39. doi: 10.1056/NEJMoa1916063 PMID: 32905675
  22. Park JJ, Kim BC, Hong SP, et al. The effect of metformin in treatment of adenomas in patients with familial adenomatous polyposis. Cancer Prev Res 2021; 14(5): 563-72. doi: 10.1158/1940-6207.CAPR-20-0580 PMID: 33509804
  23. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003; 9(13): 4756-60. PMID: 14581346
  24. Burke C, Phillips R, Berger MF, et al. Children’s International Polyposis (CHIP) study: A randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis. Clin Exp Gastroenterol 2017; 10: 177-85. doi: 10.2147/CEG.S121841 PMID: 28765715
  25. Burn J, Bishop DT, Chapman PD, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res 2011; 4(5): 655-65. doi: 10.1158/1940-6207.CAPR-11-0106 PMID: 21543343
  26. Balaguer F, Stoffel EM, Burke CA, et al. Combination of sulindac and eflornithine delays the need for lower gastrointestinal surgery in patients with familial adenomatous polyposis: Post hoc analysis of a randomized clinical trial. Dis Colon Rectum 2022; 65(4): 536-45. doi: 10.1097/DCR.0000000000002095 PMID: 34261858
  27. Cruz-Correa M, Hylind LM, Marrero JH, et al. Efficacy and safety of curcumin in treatment of intestinal adenomas in patients with familial adenomatous polyposis. Gastroenterology 2018; 155(3): 668-73. doi: 10.1053/j.gastro.2018.05.031 PMID: 29802852
  28. Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RKS. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 1995; 345(8953): 855-6. doi: 10.1016/S0140-6736(95)92989-4 PMID: 7898240
  29. Delker DA, Wood AC, Snow AK, et al. Chemoprevention with cyclooxygenase and epidermal growth factor receptor inhibitors in familial adenomatous polyposis patients: mrna signatures of duodenal neoplasia. Cancer Prev Res 2018; 11(1): 4-15. doi: 10.1158/1940-6207.CAPR-17-0130 PMID: 29109117
  30. Gilad O, Rosner G, Ivancovsky-Wajcman D, et al. Efficacy of wholistic turmeric supplement on adenomatous polyps in patients with familial adenomatous polyposis a randomized, double-blinded, placebo-controlled study. Genes 2022; 13(12): 2182. doi: 10.3390/genes13122182 PMID: 36553450
  31. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328(18): 1313-6. doi: 10.1056/NEJM199305063281805 PMID: 8385741
  32. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346(14): 1054-9. doi: 10.1056/NEJMoa012015 PMID: 11932472
  33. Ishikawa H, Wakabayashi K, Suzuki S, et al. Preventive effects of low‐dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: Double‐blind, randomized clinical trial. Cancer Med 2013; 2(1): 50-6. doi: 10.1002/cam4.46 PMID: 24133627
  34. Iwama T, Akasu T, Utsunomiya J, Muto T. Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial. Int J Clin Oncol 2006; 11(2): 133-9. doi: 10.1007/s10147-005-0548-z PMID: 16622748
  35. Keller JJ, Offerhaus GJA, Polak M, et al. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut 1999; 45(6): 822-8. doi: 10.1136/gut.45.6.822 PMID: 10562579
  36. Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995; 108(4): 1083-7. doi: 10.1016/0016-5085(95)90206-6 PMID: 7698575
  37. Lynch PM, Ayers GD, Hawk E, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 2010; 105(6): 1437-43. doi: 10.1038/ajg.2009.758 PMID: 20234350
  38. Lynch PM, Burke CA, Phillips R, et al. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut 2016; 65(2): 286-95. doi: 10.1136/gutjnl-2014-307235 PMID: 25792707
  39. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 2005; 80(12): 1618-9. doi: 10.1002/bjs.1800801244 PMID: 8298943
  40. Pasricha PJ, Bedi A, O’Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109(3): 994-8. doi: 10.1016/0016-5085(95)90411-5 PMID: 7657130
  41. Phillips RKS, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50(6): 857-60. doi: 10.1136/gut.50.6.857 PMID: 12010890
  42. Samadder NJ, Neklason DW, Boucher KM, et al. Effect of sulindac and erlotinib vs. placebo on duodenal neoplasia in familial adenomatous polyposis: A randomized clinical trial. JAMA 2016; 315(12): 1266-75. doi: 10.1001/jama.2016.2522
  43. Sinicrope FA, Half E, Morris JS, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 2004; 13(6): 920-7. doi: 10.1158/1055-9965.920.13.6
  44. Ura H, Togi S, Hatanaka H, Niida Y. Establishment of a human induced pluripotent stem cell line, KMUGMCi004-A, from a patient bearing a heterozygous c.1832delG mutation in the APC gene leading familial adenomatous polyposis (FAP). Stem Cell Res 2022; 63: 102867. doi: 10.1016/j.scr.2022.102867 PMID: 35868288
  45. Chiang JM, Chen HW, Tang RP, et al. Mutation analysis of the APC gene in Taiwanese FAP families: low incidence of APC germline mutation in a distinct subgroup of FAP families. Fam Cancer 2010; 9(2): 117-24. doi: 10.1007/s10689-009-9292-2 PMID: 19768578
  46. Yen T, Stanich PP, Axell L, Patel SG. Apc-Associated Polyposis Conditions. Apc-Associated Polyposis Conditions. In: Adam MP, Mirzaa GM, Pagon RA, et al, Eds. Genereviews(®). Seattle (WA): University of Washington, Seattle Copyright© 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved 1993.
  47. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006; 101(2): 385-98. doi: 10.1111/j.1572-0241.2006.00375.x PMID: 16454848
  48. Sheng JQ, Li SR, Yang XY, et al. Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis. Zhonghua Yi Xue Za Zhi 2006; 86(8): 526-9. PMID: 16681880
  49. Davis JS, Kanikarla-Marie P, Gagea M, et al. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer 2020; 20(1): 871. doi: 10.1186/s12885-020-07311-4 PMID: 32912193
  50. Giardiello FM. NSAID-induced polyp regression in familial adenomatous polyposis patients. Gastroenterol Clin North Am 1996; 25(2): 349-61. doi: 10.1016/S0889-8553(05)70251-X PMID: 9229577
  51. Davies NM, Gudde TW, de Leeuw MAWC. Celecoxib: A new option in the treatment of arthropathies and familial adenomatous polyposis. Expert Opin Pharmacother 2001; 2(1): 139-52. doi: 10.1517/14656566.2.1.139 PMID: 11336575
  52. Brophy JM. Celecoxib and cardiovascular risks. Expert Opin Drug Saf 2005; 4(6): 1005-15. doi: 10.1517/14740338.4.6.1005 PMID: 16255660
  53. Bannwarth B. COX-2 selective drugs and cardiovascular risks: Same data but discrepant conclusions? Expert Opin Drug Saf 2006; 5(1): 1-2. doi: 10.1517/14740338.5.1.1 PMID: 16370948
  54. van Heumen BWH, Roelofs HMJ, Vink-Börger M, et al. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: A multicentre, randomized controlled trial. Orphanet J Rare Dis 2013; 8(1): 118. doi: 10.1186/1750-1172-8-118 PMID: 23919274
  55. Seow-Choen F, Vijayan V, Keng V. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br J Surg 2005; 83(12): 1763-6. doi: 10.1002/bjs.1800831232 PMID: 9038563
  56. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355(9): 873-84. doi: 10.1056/NEJMoa061355 PMID: 16943400

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers